VC-backed Verve Therapeutics goes public
Verve Therapeutics, a biotech company focused on treating cardiovascular disease, has raised $266.7 million for its IPO after pricing its over 14 million shares at $19 per share.
Verve Therapeutics, a biotech company focused on treating cardiovascular disease, has raised $266.7 million for its IPO after pricing its over 14 million shares at $19 per share.
Copyright PEI Media
Not for publication, email or dissemination